Award of SPE2D220D0086 BICALUTAMIDE NATIONAL CONTRACT
ID: SPE2D220D0086Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA
Timeline
    Description

    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is procuring Bicalutamide National Contract. Bicalutamide is typically used as a medication for the treatment of prostate cancer.

    Point(s) of Contact
    Files
    Lifecycle
    Title
    Type
    Similar Opportunities
    Finasteride Tablets
    Active
    Dept Of Defense
    Special Notice: DEPT OF DEFENSE - DEFENSE LOGISTICS AGENCY is seeking Finasteride Tablets. Finasteride Tablets are typically used for the treatment of male pattern hair loss and benign prostatic hyperplasia. This procurement is for the incorporation of new clauses into an existing contract.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    6505--Abiraterone Acetate Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting offers for the supply of Abiraterone Acetate tablets, a pharmaceutical product critical for various government healthcare facilities, including the VA and DoD. The procurement aims to establish a reliable source through competitive contracting, requiring offerors to provide pricing for a base year and four option years, along with an NDC number for their products. Abiraterone Acetate is essential for treating specific cancers, underscoring the importance of ensuring consistent availability of this medication to support patient care. Interested vendors should contact Contract Specialist Richard Mahario at Richard.Mahario@va.gov for further details, and must comply with specific packaging, labeling, and manufacturing standards as outlined in the solicitation document.
    IBUPROFEN 400MG, 600MG, 800MG TABLETS NATIONAL CONTRACT
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking IBUPROFEN 400MG, 600MG, 800MG TABLETS. This medication is typically used for pain relief, reducing inflammation, and lowering fever. The notice is from the DEFENSE LOGISTICS AGENCY, DLA TROOP SUPPORT. The primary contact for this procurement is Denise Taubman (denise.taubman@dla.mil, 2157376877) and the secondary contact is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778). The notice includes AMENDMENT 00009 to incorporate telecommunication clauses into the solicitation.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is seeking Norgestimate/Ethinyl Estradiol Oral Tablets. These tablets are typically used for oral contraception.
    ESTRADIOL TABLETS
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is seeking ESTRADIOL TABLETS. ESTRADIOL TABLETS are typically used for hormone replacement therapy and the treatment of menopause symptoms.
    Metformin HCL
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Norgestimate/Ethinyl Estradiol Oral Tablets
    Active
    Dept Of Defense
    Special Notice DEPT OF DEFENSE is modifying contract SPE2D220D0090 to correct an administrative error for the procurement of Norgestimate/Ethinyl Estradiol Oral Tablets. Norgestimate/Ethinyl Estradiol Oral Tablets are typically used for contraception and hormone replacement therapy.
    6505--Bupropion Tablets
    Active
    Veterans Affairs, Department Of
    The Department of Veterans Affairs is soliciting proposals for the procurement of Bupropion Hydrochloride tablets, aimed at supporting veterans and related entities through its Pharmaceutical Prime Vendor Programs. Offerors are required to submit pricing that includes a 0.5% Cost Recovery Fee and provide unique National Drug Code (NDC) numbers for their products, while ensuring compliance with the Drug Supply Chain Security Act (DSCSA) and FDA regulations. This procurement is crucial for maintaining a reliable pharmaceutical supply for VA healthcare facilities, with an emphasis on participation from small and disadvantaged businesses. Interested parties can reach out to Contract Specialist Andrew J. Cazares at Andrew.Cazares@va.gov for further details.
    Valsartan
    Active
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.